MedTrace Logo

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

NCT05639166 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-05-22

No results posted yet for this study

Summary

This is a Phase 2, randomized, double-blind, multicentre, placebo-controlled study in adults to assess the safety and efficacy of inhaled IBIO123, for post-exposure prophylaxis of COVID-19.

This study aims to evaluate the efficacy and the safety of IBIO123 and the prophylaxis effect of IBIO123 in participants exposed to COVID-19 in the setting of current and uninterrupted household contacts.

Conditions

Interventions

BIOLOGICAL

IBIO123

IBIO123 10 mg

OTHER

Placebo

Matching Placebo

Sponsors & Collaborators

  • Immune Biosolutions Inc

    lead INDUSTRY

Principal Investigators

  • Sebastien Labbe, PhD · Immune Biosolutions

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-18
Primary Completion
2023-05-16
Completion
2023-05-16

Countries

  • South Africa
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05639166 on ClinicalTrials.gov